VCPIP1

Summary

VCPIP1 (valosin containing protein interacting protein 1, HGNC:30897) is a protein-coding gene on chromosome 8q13.1, encoding Deubiquitinating protein VCPIP1 (Q96JH7). Deubiquitinating enzyme involved in DNA repair and reassembly of the Golgi apparatus and the endoplasmic reticulum following mitosis. It is a selective cancer dependency (DepMap: 17.5% of cell lines).

Enables cysteine-type deubiquitinase activity. Involved in protein deubiquitination; protein-DNA covalent cross-linking repair; and regulation of protein localization to chromatin. Located in cytoplasm and nucleus.

Source: NCBI Gene 80124 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 93 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 17.5% of screened cell lines
• MANE Select transcript: NM_025054

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30897
Approved symbol	VCPIP1
Name	valosin containing protein interacting protein 1
Location	8q13.1
Locus type	gene with protein product
Status	Approved
Aliases	VCIP135, KIAA1850, FLJ23132, DUBA3
Ensembl gene	ENSG00000175073
Ensembl biotype	protein_coding
OMIM	611745
Entrez	80124

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000310421

RefSeq mRNA: 1 — MANE Select: NM_025054 NM_025054

CCDS: CCDS6192

Canonical transcript exons

ENST00000310421 — 3 exons

Exon	Start	End
ENSE00001192704	66651458	66651544
ENSE00001218890	66628487	66635372
ENSE00001218896	66664249	66667231

Expression profiles

Bgee: expression breadth ubiquitous, 225 present calls, max score 90.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.7037 / max 210.1298, expressed in 1730 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
93418	5.4702	1605
93416	2.2459	726
93417	1.9668	1017
93415	1.0207	145

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	90.74	gold quality
tendon	UBERON:0000043	88.38	gold quality
endothelial cell	CL:0000115	87.93	gold quality
calcaneal tendon	UBERON:0003701	87.58	gold quality
adrenal tissue	UBERON:0018303	86.24	gold quality
secondary oocyte	CL:0000655	85.63	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.42	gold quality
monocyte	CL:0000576	82.64	gold quality
leukocyte	CL:0000738	82.60	gold quality
mononuclear cell	CL:0000842	82.34	gold quality
oocyte	CL:0000023	82.03	gold quality
middle temporal gyrus	UBERON:0002771	80.79	gold quality
medial globus pallidus	UBERON:0002477	80.77	gold quality
Brodmann (1909) area 23	UBERON:0013554	80.37	gold quality
cortical plate	UBERON:0005343	79.67	gold quality
stromal cell of endometrium	CL:0002255	78.61	gold quality
granulocyte	CL:0000094	78.50	gold quality
colonic epithelium	UBERON:0000397	78.42	gold quality
ventricular zone	UBERON:0003053	78.06	gold quality
blood	UBERON:0000178	77.72	gold quality
islet of Langerhans	UBERON:0000006	77.71	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.70	gold quality
primary visual cortex	UBERON:0002436	77.26	gold quality
gastrocnemius	UBERON:0001388	76.93	gold quality
esophagus squamous epithelium	UBERON:0006920	76.88	gold quality
ganglionic eminence	UBERON:0004023	76.60	gold quality
muscle of leg	UBERON:0001383	76.31	gold quality
lymph node	UBERON:0000029	76.14	gold quality
hindlimb stylopod muscle	UBERON:0004252	75.84	gold quality
globus pallidus	UBERON:0001875	75.39	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.23
E-GEOD-106540	no	947.79

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

244 targeting VCPIP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 17.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 5)

• evidence of tyrosine phosphorylation during sperm capacitation (PMID:12509440)
• the phosphorylation of VCIP135 on Threonine-760 and Serine-767 inhibits p97-mediated Golgi membrane fusion at mitosis (PMID:23500464)
• VCIP135 phosphorylation regulates its Golgi membrane association and p97 interaction, and thus contributes to the tight control of the Golgi disassembly and reassembly process during the cell cycle. (PMID:24163436)
• Phosphorylation and ubiquitination are coordinated via VCIP135 to control Golgi membrane dynamics in the cell cycle. (PMID:25904330)
• BoNT/A catalytic light chain binds to, and is a substrate for, the ubiquitin ligase HECTD2. However, the light chain evades proteasomal degradation by the dominant effect of a deubiquitinating enzyme, VCIP135/VCPIP1. This deubiquitinating enzyme binds BoNT/A light chain directly. (PMID:28584101)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	vcpip1	ENSDARG00000060177
mus_musculus	Vcpip1	ENSMUSG00000045210
rattus_norvegicus	Vcpip1	ENSRNOG00000006980

Protein

Protein identifiers

Deubiquitinating protein VCPIP1 — Q96JH7 (reviewed: Q96JH7)

Alternative names: Valosin-containing protein p97/p47 complex-interacting protein 1, Valosin-containing protein p97/p47 complex-interacting protein p135

All UniProt accessions (1): Q96JH7

UniProt curated annotations — full annotation on UniProt →

Function. Deubiquitinating enzyme involved in DNA repair and reassembly of the Golgi apparatus and the endoplasmic reticulum following mitosis. Necessary for VCP-mediated reassembly of Golgi stacks after mitosis. Plays a role in VCP-mediated formation of transitional endoplasmic reticulum (tER). Mediates dissociation of the ternary complex containing STX5A, NSFL1C and VCP. Also involved in DNA repair following phosphorylation by ATM or ATR: acts by catalyzing deubiquitination of SPRTN, thereby promoting SPRTN recruitment to chromatin and subsequent proteolytic cleavage of covalent DNA-protein cross-links (DPCs). Hydrolyzes ‘Lys-11’- and ‘Lys-48’-linked polyubiquitin chains. (Microbial infection) Regulates the duration of C.botulinum neurotoxin type A (BoNT/A) intoxication by catalyzing deubiquitination of Botulinum neurotoxin A light chain (LC), thereby preventing LC degradation by the proteasome, and accelerating botulinum neurotoxin intoxication in patients.

Subunit / interactions. Binds VCP and the ternary complex containing STX5A, NSFL1C and VCP.

Subcellular location. Nucleus. Cytoplasm. Endoplasmic reticulum. Golgi apparatus. Golgi stack.

Post-translational modifications. Phosphorylated at Ser-1207 by ATM or ATR following induction of covalent DNA-protein cross-links (DPCs).

RefSeq proteins (1): NP_079330* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003323	OTU_dom	Domain
IPR029071	Ubiquitin-like_domsf	Homologous_superfamily
IPR039087	VCPIP1	Family
IPR045827	VCPIP1_N	Domain
IPR048857	OTU1_Ubl	Domain

Pfam: PF02338, PF19437, PF21403

UniProt features (91 total): helix 23, strand 21, modified residue 10, turn 10, compositionally biased region 9, region of interest 6, sequence conflict 5, active site 3, mutagenesis site 2, chain 1, domain 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
9MPR	ELECTRON MICROSCOPY	2.9
9MPS	ELECTRON MICROSCOPY	2.9
9MPT	ELECTRON MICROSCOPY	3.1
9MPV	ELECTRON MICROSCOPY	3.1
9DIL	ELECTRON MICROSCOPY	3.3
9MQ6	ELECTRON MICROSCOPY	3.3
8YKA	ELECTRON MICROSCOPY	3.45

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96JH7-F1	70.38	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 216; 219 (nucleophile); 354

Post-translational modifications (10): 408, 747, 757, 763, 768, 994, 998, 1077, 1198, 1207

Mutagenesis-validated functional residues (2):

Position	Phenotype
219	loss of deubiquitinating activity and ability to deubiquitinate sprtn.
1207	abolished phosphorylation in response to covalent dna-protein cross-links (dpcs).

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5689896	Ovarian tumor domain proteases

MSigDB gene sets: 240 (showing top): TGCGCANK_UNKNOWN, AAGTCCA_MIR422B_MIR422A, TTTGTAG_MIR520D, GOBP_MEMBRANE_FUSION, GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_REMOVAL, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP, ATGTTAA_MIR302C, AACWWCAANK_UNKNOWN, AGTCTTA_MIR499, FOSTER_TOLERANT_MACROPHAGE_UP, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOBP_PROTEIN_LOCALIZATION_TO_CHROMATIN, GOMF_CYSTEINE_TYPE_PEPTIDASE_ACTIVITY, GOBP_ORGANELLE_MEMBRANE_FUSION, GOBP_PROTEIN_LOCALIZATION_TO_CHROMOSOME

GO Biological Process (12): proteolysis (GO:0006508), DNA damage response (GO:0006974), endoplasmic reticulum membrane fusion (GO:0016320), protein ubiquitination (GO:0016567), protein deubiquitination (GO:0016579), protein K11-linked deubiquitination (GO:0035871), protein K48-linked deubiquitination (GO:0071108), Golgi reassembly (GO:0090168), protein-DNA covalent cross-linking repair (GO:0106300), regulation of protein localization to chromatin (GO:1905634), DNA repair (GO:0006281), Golgi organization (GO:0007030)

GO Molecular Function (6): cysteine-type deubiquitinase activity (GO:0004843), catalytic activity (GO:0003824), protein binding (GO:0005515), peptidase activity (GO:0008233), cysteine-type peptidase activity (GO:0008234), hydrolase activity (GO:0016787)

GO Cellular Component (6): nucleus (GO:0005634), cytoplasm (GO:0005737), endoplasmic reticulum lumen (GO:0005788), Golgi stack (GO:0005795), endoplasmic reticulum (GO:0005783), Golgi apparatus (GO:0005794)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Deubiquitination	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	3
protein deubiquitination	2
cytoplasm	2
endomembrane system	2
protein metabolic process	1
cellular response to stress	1
endoplasmic reticulum organization	1
endoplasmic reticulum membrane organization	1
organelle membrane fusion	1
protein modification by small protein conjugation	1
cysteine-type deubiquitinase activity	1
protein modification by small protein removal	1
Golgi organization	1
cellular component assembly	1
Golgi inheritance	1
DNA repair	1
regulation of protein localization	1
protein localization to chromatin	1
DNA metabolic process	1
DNA damage response	1
organelle organization	1
endomembrane system organization	1
cysteine-type peptidase activity	1
deubiquitinase activity	1
molecular_function	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
catalytic activity	1
intracellular anatomical structure	1
cellular anatomical structure	1
endoplasmic reticulum	1
intracellular organelle lumen	1
Golgi apparatus subcompartment	1

Protein interactions and networks

STRING

1336 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
VCPIP1	VCP	P55072	951
VCPIP1	STX5	Q13190	941
VCPIP1	NSFL1C	Q9UNZ2	875
VCPIP1	NPLOC4	Q8TAT6	771
VCPIP1	BET1L	Q9NYM9	769
VCPIP1	UFD1	Q92890	738
VCPIP1	GOLGA2	Q08379	724
VCPIP1	FAF2	Q96CS3	660
VCPIP1	ATXN3L	Q9H3M9	653
VCPIP1	ATXN3	P54252	652
VCPIP1	YOD1	Q5VVQ6	620
VCPIP1	OTUD6B	Q8N6M0	609
VCPIP1	USP7	Q93009	592
VCPIP1	USP50	Q70EL3	590
VCPIP1	OTUD6A	Q7L8S5	570

IntAct

123 interactions, top by confidence:

A	B	Type	Score
UBXN6	VCP	psi-mi:“MI:0914”(association)	0.960
FAF2	VCP	psi-mi:“MI:0914”(association)	0.870
RFXANK	RFXAP	psi-mi:“MI:0914”(association)	0.780
MED23	MED19	psi-mi:“MI:2364”(proximity)	0.770
UBXN1	VCP	psi-mi:“MI:0914”(association)	0.740
UBXN8	VCP	psi-mi:“MI:0914”(association)	0.690
VCP	UBXN8	psi-mi:“MI:0914”(association)	0.690
INSRR	INSR	psi-mi:“MI:0914”(association)	0.650
FAF1	VCP	psi-mi:“MI:0914”(association)	0.640
TTLL1	CDC27	psi-mi:“MI:0914”(association)	0.640
PRMT2	SAMD1	psi-mi:“MI:0914”(association)	0.640
CCT7	TXNDC9	psi-mi:“MI:0914”(association)	0.640
PLAAT5	VCPIP1	psi-mi:“MI:0915”(physical association)	0.590
VCPIP1	SPG11	psi-mi:“MI:0915”(physical association)	0.550
MAF1	POLR3A	psi-mi:“MI:0914”(association)	0.530
CNKSR3	COLGALT2	psi-mi:“MI:0914”(association)	0.530
VCPIP1	VCP	psi-mi:“MI:0914”(association)	0.530
MCL1	PRKAG1	psi-mi:“MI:0914”(association)	0.530
LRCH3	LRCH2	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
S100A4	OIP5	psi-mi:“MI:0914”(association)	0.530
VCPIP1	iglC2	psi-mi:“MI:0915”(physical association)	0.370
GSK3A	VCPIP1	psi-mi:“MI:0915”(physical association)	0.370
VCPIP1	SMAD9	psi-mi:“MI:0915”(physical association)	0.370
KIF20B	ACSL3	psi-mi:“MI:0914”(association)	0.350
LGALS3BP	CEP290	psi-mi:“MI:0914”(association)	0.350

BioGRID (215): VCPIP1 (Affinity Capture-RNA), VCPIP1 (Affinity Capture-RNA), VCP (Affinity Capture-Western), VCPIP1 (Affinity Capture-MS), VCPIP1 (Affinity Capture-MS), VCPIP1 (Affinity Capture-MS), VCPIP1 (Affinity Capture-MS), VCPIP1 (Affinity Capture-MS), VCPIP1 (Affinity Capture-MS), VCPIP1 (Proximity Label-MS), VCPIP1 (Proximity Label-MS), VCPIP1 (Proximity Label-MS), VCPIP1 (Proximity Label-MS), VCPIP1 (Proximity Label-MS), VCPIP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A5F9C6I2, A1L3F5, A2BDA5, A3KGS3, A8E4X8, D3ZXK7, F1R7R1, O75129, P21359, P51593, P97526, Q04690, Q1JPG0, Q2PPJ7, Q3SZD5, Q4QQM5, Q4R5A4, Q5RC14, Q5XPI3, Q5XPI4, Q62717, Q66K64, Q6GLR7, Q6NXD8, Q6P4S8, Q6PFH3, Q6VNB8, Q7L4E1, Q7TMY8, Q7Z6Z7, Q80TJ1, Q86UW7, Q8BHR8, Q8BK03, Q8BYR5, Q8CDG3, Q8CF97, Q8CID0, Q8IY22, Q8IZQ1

Diamond homologs: Q8CDG3, Q8CF97, Q96JH7

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CDK1	“down-regulates activity”	VCPIP1	phosphorylation
VCPIP1	“up-regulates activity”	VCP	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	84
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

793 predictions. Top by Δscore:

Variant	Effect	Δscore
8:66635222:ACAG:A	donor_gain	1.0000
8:66635223:CAGC:C	donor_gain	1.0000
8:66635369:ATACC:A	acceptor_loss	1.0000
8:66635370:TACCT:T	acceptor_loss	1.0000
8:66635371:ACCTA:A	acceptor_loss	1.0000
8:66635222:A:AC	donor_gain	0.9900
8:66635223:C:CC	donor_gain	0.9900
8:66635223:CAG:C	donor_gain	0.9900
8:66635249:TCAGG:T	donor_gain	0.9900
8:66635269:T:TA	donor_gain	0.9900
8:66635368:CATAC:C	acceptor_gain	0.9900
8:66635370:TAC:T	acceptor_gain	0.9900
8:66635374:T:G	acceptor_loss	0.9900
8:66651451:A:C	donor_gain	0.9900
8:66651490:C:CT	donor_gain	0.9900
8:66651491:C:CT	donor_gain	0.9900
8:66651493:C:A	donor_gain	0.9900
8:66651542:CTC:C	acceptor_gain	0.9900
8:66651544:CCTGT:C	acceptor_loss	0.9900
8:66651545:C:CC	acceptor_gain	0.9900
8:66651545:CTGT:C	acceptor_loss	0.9900
8:66651546:T:A	acceptor_loss	0.9900
8:66635189:CTT:C	donor_gain	0.9800
8:66635191:T:TA	donor_gain	0.9800
8:66635373:C:CC	acceptor_gain	0.9800
8:66651452:CTATA:C	donor_loss	0.9800
8:66651453:TATAC:T	donor_loss	0.9800
8:66651454:ATACC:A	donor_loss	0.9800
8:66651455:TA:T	donor_loss	0.9800
8:66651456:A:AG	donor_loss	0.9800

AlphaMissense

8011 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:66651502:A:G	F918S	1.000
8:66651533:A:G	W908R	1.000
8:66651533:A:T	W908R	1.000
8:66664506:C:G	R818P	1.000
8:66665007:A:C	I651R	1.000
8:66665007:A:T	I651K	1.000
8:66665019:A:T	V647D	1.000
8:66665045:A:C	F638L	1.000
8:66665045:A:T	F638L	1.000
8:66665047:A:G	F638L	1.000
8:66665057:A:C	F634L	1.000
8:66665057:A:T	F634L	1.000
8:66665058:A:G	F634S	1.000
8:66665059:A:G	F634L	1.000
8:66665070:A:T	V630D	1.000
8:66665073:A:G	L629P	1.000
8:66665129:G:C	F610L	1.000
8:66665129:G:T	F610L	1.000
8:66665131:A:G	F610L	1.000
8:66665134:A:G	W609R	1.000
8:66665134:A:T	W609R	1.000
8:66665167:A:G	W598R	1.000
8:66665167:A:T	W598R	1.000
8:66665347:A:G	C538R	1.000
8:66665554:A:G	C469R	1.000
8:66665664:A:T	V432D	1.000
8:66665827:A:G	W378R	1.000
8:66665827:A:T	W378R	1.000
8:66665918:C:A	W347C	1.000
8:66665918:C:G	W347C	1.000

dbSNP variants (sampled 300 via entrez): RS1000182571 (8:66663182 T>C,G), RS1000310387 (8:66652574 T>C), RS1000344141 (8:66658514 G>A), RS1000357975 (8:66637843 G>T), RS1000371243 (8:66653303 A>T), RS1000444986 (8:66656355 C>T), RS1000671304 (8:66657385 C>T), RS1000919438 (8:66665236 C>T), RS1001045465 (8:66633103 T>C), RS1001075945 (8:66637507 T>C), RS1001130338 (8:66644710 A>C), RS1001277942 (8:66640099 A>T), RS1001344373 (8:66659833 G>A), RS1001348746 (8:66651672 G>A), RS1001351218 (8:66629862 G>T)

Disease associations

OMIM: gene MIM:611745 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4630849 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Valproic Acid	decreases expression, decreases methylation	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	affects phosphorylation	1
daidzein	affects cotreatment, increases expression	1
bisphenol A	decreases expression	1
trichostatin A	affects expression	1
daidzin	increases expression, affects cotreatment	1
butyraldehyde	decreases expression	1
tetrabromobisphenol A	decreases expression	1
zinc chromate	increases abundance, increases expression	1
coumarin	decreases phosphorylation	1
genistin	affects cotreatment, increases expression	1
chromium hexavalent ion	increases abundance, increases expression	1
glycitein	affects cotreatment, increases expression	1
monomethylarsonous acid	increases expression	1
glycitin	affects cotreatment, increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
jinfukang	decreases expression	1
Arsenic Trioxide	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases expression	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression	1
Clorgyline	increases expression	1
Formaldehyde	decreases expression	1
Plant Oils	increases expression	1
Quercetin	decreases phosphorylation	1
Tobacco Smoke Pollution	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4606002	Binding	Inhibition of human GST-tagged VCPIP CD (25 to 561 residues) expressed in Escherichia coli assessed as cleavage of Ubiquitin-Rhodamine110-glycine to Ubiquitin and Rhodamine110-glycine using Ubiquitin-Rhodamine110-glycine as substrate by flu	Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity. — J Med Chem

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2KZ	Abcam HeLa VCPIP1 KO	Cancer cell line	Female
CVCL_F1UJ	HyCyte THP-1 KO-hVCPIP1	Cancer cell line	Male
CVCL_TX35	HAP1 VCPIP1 (-) 1	Cancer cell line	Male
CVCL_TX36	HAP1 VCPIP1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.